Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GZR4 PK and Safety in Hepatic Impairment
NCT07193147Phase 1Active, not recruiting
- Sponsor
- Gan & Lee Pharmaceuticals
- Start
- Oct 2025
- Primary completion
- Jul 2026
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of GZR4 in type 2 diabetes mellitus (T2DM), sponsored by Gan & Lee Pharmaceuticals. Primary endpoints: Maximum Plasma Concentration and Area Under the Curve from time zero to last quantifiable concentration. Started Oct 2025; status: active, not recruiting.
02
Drugs
GZR4
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT07193147.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07193147.